Product News: Deep Learning-Based Genedata Imagence, for Automated High-Content Image Analysis, Debuts at SLAS Conference

Innovative software solution enables efficient analysis of phenotypic high-content screens

24 Oct 2018


Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D, has announced Genedata Imagence®, the industry’s first commercial and instrument-agnostic software that automates the analysis of high-content screening (HCS) images.

The deep learning-based solution accelerates, by orders of magnitude, the time-consuming and complex process of analyzing phenotypic high-content images. Delivering reproducible, unbiased results proven to be equal to or better than results from more traditional analysis approaches, the solution enables biologists to quickly and routinely set up and analyze high-content screens without requiring image analysis expertise. Genedata Imagence will be demonstrated at the SLAS Advanced 3D Human Models and High-Content Analysis Conference.

Game changer: genedata imagence reduces analysis time from weeks to hours

Genedata Imagence is the result of several collaborations between Genedata and leaders in the biopharmaceutical industry who had expressed the need for a more efficient HCS image analysis process. To address this need, Genedata invested significant resources in developing Genedata Imagence – the first commercial software solution that meets key requirements for this specific process. A joint project with AstraZeneca, based on Genedata Imagence technology, was awarded the 2018 Bio-IT World Best Practices Award for the innovation and value that the solution brings to the industry.

This project demonstrated how the technology can automatically transfer learnings from one assay to another, allowing a very rapid set-up of analysis workflows for new assays. The deep learning-based solution was tested and proven with pharmacologically relevant parameters used on a very typical workflow for assay development. This collaboration also validated in real-life settings the quality of results generated by Genedata Imagence. 

Deep learning has the potential to be a real game changer when applied to the analysis of phenotypic high-content screens. Genedata collaboration partners identify value in three key areas: the ability to increase the speed at which data are processed and reduce the time it takes to fine-tune assays; elimination of human bias; and most importantly, enabling scientists to better understand and examine specific cell biology.

Ultimately, Genedata Imagence will enable pharmaceutical R&D groups to broadly implement and automate the analysis of phenotypic high content screens and significantly scale-up their HCS operations, thereby reducing time consuming, labor intensive work while fueling faster delivery of R&D projects. 

Interested parties can explore the technology through the Genedata Early Access program. The program allows customers early adoption of Genedata Imagence to their own projects and provides an opportunity to learn how the solution can improve existing workflows. The software is scheduled for licensing in early 2019.

“With Genedata Imagence, we provide a highly innovative solution for HCS image analysis that will revolutionize a key process in biopharmaceutical R&D,” said Dr. Othmar Pfannes, CEO of Genedata. “We are committed to using cutting-edge technologies such as AI and deep learning that drive improved efficiencies in biopharmaceutical R&D processes, and eager to advance further collaborations to this end with industry leaders.” 

Click here to register free as a SelectScience member and get the latest news direct to your inbox >